Clinical assessment of new antineuropathic strategies for chemotherapy-induced peripheral neuropathy: pain should not be the principal endpoint

Pain. 2017 Jan;158(1):180-182. doi: 10.1097/j.pain.0000000000000743.

Authors

Nicolas Kerckhove¹, Bruno Pereira², Denis Pezet³, David Balayssac¹

Affiliations

¹ Université Clermont Auvergne, Inserm, U1107, NEURO-DOL, CHU Clermont-Ferrand, délégation à la recherche clinique et à l'innovation, Clermont-Ferrand, France.
² CHU Clermont-Ferrand, délégation à la recherche clinique et à l'innovation, Clermont-Ferrand, France.
³ Université Clermont Auvergne, Inserm, U1071, USC INRA 2018, M2iSH, CHU Clermont-Ferrand, service de chirurgie et oncologie digestive, Clermont-Ferrand, France.

PMID: 27984530
DOI: 10.1097/j.pain.0000000000000743

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Agents
Humans
Pain*
Peripheral Nervous System Diseases / chemically induced*

Substances

Antineoplastic Agents